Bookedited by Maurizio Pocchiari, Jean Manson.
Summary: Human Prion Diseases, Volume 153 is designed to update the reader on the latest advances and clinical aspects of prion diseases. The book is organized into five sections, including the pathophysiology of prions and a description of animal and human diseases. This is followed by detailed reports on recent advances in diagnosis strategies for the development of novel anti-prion molecules and possible designs of clinical trials in such a rare disease. An introductory chapter gives an extensive historical background of prion research, with a final chapter highlighting recent progress, and more importantly, unsolved problems"--Publisher's description.
Contents:
Historical view
Section I: Pathophysiology of prions. The cellular and pathological prion protein
Cell biology of prion infection
Experimental models of human prion diseases and prion strains
The role of the immune system in prion infection
Section II: Animal prion diseases (clinical, epidemiology, neuropathological, biochemical, biomarker, and genotypes). Typical and atypical scrapie
Typical and atypical BSE
Chronic Wasting Disease
Section III: Human prion diseases (clinical, epidemiology, neuropathological, biochemical, biomarker, and genotypes). Sporadic Creutzfeldt-Jakob Disease
Variably protease-sensitive prionopathy
Variant Creutzfeldt-Jakob Disease
Iatrogenic Creutzfeldt-Jakob Disease
Genetic Creutzfeldt-Jakob Disease
Gerstmann-Sträussler-Scheinker disease
Sporadic and fatal Familial Insomnia
Section IV: Prion-like mechanisms in other neurodegenerative diseases. Prion-like mechanisms in Alzheimer
Prion-like mechanisms in Parkinson
Prion-like mechanisms in ALS
Section V: Diagnosis and treatment. Prion protein amplification techniques
Differential diagnosis with other rapid progressive dementias
Symptomatic treatment, care and support of CJD patients
Identifying therapeutic targets and treatment in model systems
Vaccination strategies
Clinical trials
Section VI: Public health issues. Animal diseases and the zoonotic potential
Safety of blood, blood derivatives and plasma-derived products
Safety in clinical practice
Concluding thoughts.